Parasite clearance after malaria therapy: Staying a step ahead of drug resistance

BMC Medicine

Volumn 13, Issue 1, 2015, Pages

  Karunajeewa, Harin A ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b WESTERN HEALTH   (Australia)

Author keywords

Antimalarial; Artemisinin combination therapy; Falciparum; Malaria; Parasite clearance

Indexed keywords

ARTEMISININ DERIVATIVE; ANTIMALARIAL AGENT;

AFRICA; AFRICAN; ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; CLINICAL TRIAL (TOPIC); DATA ANALYSIS; DRUG USE; HUMAN; IN VITRO STUDY; MALARIA; MICROSCOPY; NOTE; PARASITE CLEARANCE; PLASMODIUM FALCIPARUM; SOUTHEAST ASIA; MALARIA, FALCIPARUM; MALE;

ANTIMALARIALS; ARTEMISININS; HUMANS; MALARIA, FALCIPARUM; MALE;

EID: 84942684018     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-015-0486-1     Document Type: Note

References (16)

1. World Health Organization. World Malaria Report 2014. Geneva: WHO; 2014. http://www.who.int/malaria/publications/world_malaria_report_2014/en/.
2. Karunajeewa HK. Artemisinins: artemisinin, dihydroartemisinin, artemether and artesunate. In: Staines H, Krishna S, editors. Treatment and prevention of malaria antimalarial drug chemistry, action and use, vol. 1. 1st ed. Basel: Springer; 2012. p. 157-80.
3. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, et al. Averting a malaria disaster. Lancet. 1999;353:1965-7.
4. World Health Organization. Guidelines for the treatment of malaria. Third edition. Geneva: WHO; 2015. http://www.who.int/malaria/publications/atoz/9789241549127/en/.
5. Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, et al. A research agenda to underpin malaria eradication. PLoS Med. 2011;8, e1000406.
6. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411-23.
7. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619-20.
8. Chaorattanakawee S, Saunders DL, Sea D, Chanarat N, Yingyuen K, Sundrakes S, et al. Ex vivo drug susceptibility testing and molecular profiling of clinical plasmodium falciparum isolates from Cambodia from 2008 to 2013 suggest emerging piperaquine resistance. Antimicrob Agents Chemother. 2015;59:4631-43.
9. Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, et al. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis. 2015;15:683-91.
10. Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect Dis. 2013;13:1043-9.
11. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50-5.
12. Flegg JA, Guerin PJ, White NJ, Stepniewska K. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J. 2011;10:339.
13. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother. 1997;41:1413-22.
14. World Health Organization. Methods for surveillance of antimalarial drug efficacy. Geneva: WHO; 2009. http://www.who.int/malaria/publications/atoz/9789241597531/en/.
15. WWARN Artemisinin based Combination Therapy (ACT) Africa Baseline Study Group. Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated malaria: a meta-analysis of individual patient data. BMC Med. 2015;13:212.
16. Hastings IM, Kay K, Hodel EM. How robust are malaria parasite clearance rates as indicators of drug effectiveness and resistance? Antimicrob Agents Chemother. 2015. Ahead of print.